The Readout Loud
322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
STAT reporter Matt Herper joins us to break down all the angles of this week's tumultuous week in cancer immunotherapy, including his up-close look at Summit co-CEO Bob Duggan. We also discuss the latest news in the life sciences, including Moderna pruning its pipeline and its spending, plus results from a study that tested a GLP-1 drug in children.